Antitumoral analogs of lamellarins

摘要

New lamellarins are provided of the general formula III wherein X is selected from the group consisting of N, O and S; wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and R₉ are each independently selected from the group consisting of H, OH, OR', SH, SR', SO₂R', NHR', N(R')₂, N-R', NHCOR', N(COR')₂, NHS0₂R', N0₂, PO(R'₂, P0₂R', C(=0)H, C(=0)R', C0₂H, C0₂R', OPO(R')₂, OP0₂R', OC(=0)H, OC(=0)R', N-C(R')₂, substituted or unsubstituted C₁-C₁₂ alkyl, substituted or unsubstituted C₁-C₁₂ haloalkyl, substituted or unsubstituted C₂-C₁₂ alkenyl, substituted or unsubstituted C₂-C₁₂ alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, N0₂, NH₂, SH, CN, halogen, =0, C(=0)H, C(-O)CH₃, C0₂H, C(=0)R', substituted or unsubstituted C₁-C₁₈ alkyl, substituted or unsubstituted C₂-C₁₈ alkenyl, substituted or unsubstituted C₂-C₁₈ alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted C₁-C₁₈ alkoxyl, substituted or unsubstituted C₁-C₁₈ aminoalkyl, substituted or unsubstituted C₁-C₁₈ aminoacid, substituted or unsubstituted C₁-C₁₈ thioalkyl, substituted or unsubstituted C₁-C₁₈ alkylsulfinyl, substituted or unsubstituted C₁-C₁₈ alkylsulfonyl; wherein the pairs of groups R₁ and R₂, R₂ and R₃, R₃ and R₄, R₃ and R₉, R₄ and R₉, R₉ and R₅, R₉ and R₆, or R₆ and R₇, R₇ and R₈ may be joined into a carbocyclic or heterocyclic ring system; and the dotted line represents an single or double bond; or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.